Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2024

Open Access 01-12-2024 | Pulmonary Hypertension | Research

Fractional exhaled nitric oxide in idiopathic pulmonary arterial hypertension and mixed connective tissue disease complicating pulmonary hypertension

Authors: Jianhua Xu, Xingxing Sun, Yuan Cao, Hanqing Zhu, Wenlan Yang, Jinming Liu, Jian Guo

Published in: BMC Pulmonary Medicine | Issue 1/2024

Login to get access

Abstract

Background

Fractional exhaled nitric oxide (FeNO) has been extensively studied in various causes of pulmonary hypertension (PH), but its utility as a noninvasive marker remains highly debated. The objective of our study was to assess FeNO levels in patients with idiopathic pulmonary arterial hypertension (IPAH) and mixed connective tissue disease complicating pulmonary hypertension (MCTD-PH), and to correlate them with respiratory functional data, disease severity, and cardiopulmonary function.

Methods

We collected data from 54 patients diagnosed with IPAH and 78 patients diagnosed with MCTD-PH at the Shanghai Pulmonary Hospital Affiliated to Tongji University. Our data collection included measurements of brain natriuretic peptide (pro-BNP), cardiopulmonary exercise test (CPET), pulmonary function test (PFT), impulse oscillometry (IOS), and FeNO levels. Additionally, we assessed World Health Organization functional class (WHO-FC) of each patient.

Results

(1) The fractional exhaled concentration of nitric oxide was notably higher in patients with IPAH compared to those with MCTD-PH. Furthermore, within the IPAH group, FeNO levels were found to be lower in cases of severe IPAH compared to mild IPAH (P = 0.024); (2) In severe pulmonary hypertension as per the WHO-FC classification, FeNO levels in IPAH exhibited negative correlations with FEV1/FVC (Forced Expiratory Velocity at one second /Forced Vital Capacity), MEF50% (Maximum Expiratory Flow at 50%), MEF25%, and MMEF75/25% (Maximum Mid-expiratory Flow between 75% and 25%), while in severe MCTD-PH, FeNO levels were negatively correlated with R20% (Resistance at 20 Hz); (3) ROC (Receiving operator characteristic curve) analysis indicated that the optimal cutoff value of FeNO for diagnosing severe IPAH was 23ppb; (4) While FeNO levels tend to be negatively correlated with peakPETO2(peak end-tidal partial pressure for oxygen) in severe IPAH, in mild IPAH they had a positive correlation to peakO2/Heart rate (HR). An interesting find was observed in cases of severe MCTD-PH, where FeNO levels were negatively correlated with HR and respiratory exchange ratio (RER), while positively correlated with O2/HR throughout the cardiopulmonary exercise test.

Conclusion

FeNO levels serve as a non-invasive measure of IPAH severity. Although FeNO levels may not assess the severity of MCTD-PH, their significant makes them a valuable tool when assessing severe MCTD-PH.
Literature
1.
go back to reference Levine DJ. Pulmonary arterial hypertension: updates in epidemiology and evaluation of patients. Am J Manag Care. 2021;27(3 Suppl):S35–41.PubMed Levine DJ. Pulmonary arterial hypertension: updates in epidemiology and evaluation of patients. Am J Manag Care. 2021;27(3 Suppl):S35–41.PubMed
2.
go back to reference Carpagnano GE, Radaeli A, Lacedonia D, Correale M, Carpagnano G, Palmiotti A, et al. Exhaled nitric oxide and exhaled Breath temperature as potential biomarkers in patients with pulmonary hypertension. Biomed Res Int. 2018;2018:7292045.CrossRefPubMedPubMedCentral Carpagnano GE, Radaeli A, Lacedonia D, Correale M, Carpagnano G, Palmiotti A, et al. Exhaled nitric oxide and exhaled Breath temperature as potential biomarkers in patients with pulmonary hypertension. Biomed Res Int. 2018;2018:7292045.CrossRefPubMedPubMedCentral
3.
go back to reference Galiè N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Eur Heart J. 2004;25(24):2243–78.CrossRefPubMed Galiè N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Eur Heart J. 2004;25(24):2243–78.CrossRefPubMed
4.
go back to reference Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61(1). Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61(1).
5.
go back to reference Jing ZC, Xu XQ, Badesch DB, Jiang X, Wu Y, Liu JM, et al. Pulmonary function testing in patients with pulmonary arterial hypertension. Respir Med. 2009;103(8):1136–42.CrossRefPubMed Jing ZC, Xu XQ, Badesch DB, Jiang X, Wu Y, Liu JM, et al. Pulmonary function testing in patients with pulmonary arterial hypertension. Respir Med. 2009;103(8):1136–42.CrossRefPubMed
6.
go back to reference Meyer FJ, Ewert R, Hoeper MM, Olschewski H, Behr J, Winkler J, et al. Peripheral airway obstruction in primary pulmonary hypertension. Thorax. 2002;57(6):473–6.CrossRefPubMedPubMedCentral Meyer FJ, Ewert R, Hoeper MM, Olschewski H, Behr J, Winkler J, et al. Peripheral airway obstruction in primary pulmonary hypertension. Thorax. 2002;57(6):473–6.CrossRefPubMedPubMedCentral
7.
go back to reference Ruaro B, Salton F, Baratella E, Confalonieri P, Geri P, Pozzan R et al. An overview of different techniques for improving the treatment of pulmonary hypertension secondary in systemic sclerosis patients. Diagnostics (Basel, Switzerland). 2022;12(3). Ruaro B, Salton F, Baratella E, Confalonieri P, Geri P, Pozzan R et al. An overview of different techniques for improving the treatment of pulmonary hypertension secondary in systemic sclerosis patients. Diagnostics (Basel, Switzerland). 2022;12(3).
8.
go back to reference Klinger JR. The nitric oxide/cGMP signaling pathway in pulmonary hypertension. Clin Chest Med. 2007;28(1):143–67. ix.CrossRefPubMed Klinger JR. The nitric oxide/cGMP signaling pathway in pulmonary hypertension. Clin Chest Med. 2007;28(1):143–67. ix.CrossRefPubMed
9.
go back to reference Klinger JR, Abman SH, Gladwin MT. Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2013;188(6):639–46.CrossRefPubMed Klinger JR, Abman SH, Gladwin MT. Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2013;188(6):639–46.CrossRefPubMed
10.
go back to reference Janaszak-Jasiecka A, Siekierzycka A, Płoska A, Dobrucki IT, Kalinowski L. Endothelial Dysfunction Driven by Hypoxia-The Influence of Oxygen Deficiency on NO Bioavailability. Biomolecules. 2021;11(7). Janaszak-Jasiecka A, Siekierzycka A, Płoska A, Dobrucki IT, Kalinowski L. Endothelial Dysfunction Driven by Hypoxia-The Influence of Oxygen Deficiency on NO Bioavailability. Biomolecules. 2021;11(7).
11.
go back to reference Escamilla-Gil JM, Fernandez-Nieto M, Acevedo N. Understanding the Cellular sources of the Fractional exhaled nitric oxide (FeNO) and its role as a biomarker of type 2 inflammation in Asthma. Biomed Res Int. 2022;2022:5753524.CrossRefPubMedPubMedCentral Escamilla-Gil JM, Fernandez-Nieto M, Acevedo N. Understanding the Cellular sources of the Fractional exhaled nitric oxide (FeNO) and its role as a biomarker of type 2 inflammation in Asthma. Biomed Res Int. 2022;2022:5753524.CrossRefPubMedPubMedCentral
12.
go back to reference Ji L, Su S, Xin M, Zhang Z, Nan X, Li Z, et al. Luteolin ameliorates hypoxia-induced pulmonary hypertension via regulating HIF-2α-Arg-NO axis and PI3K-AKT-eNOS-NO signaling pathway. Phytomedicine: Int J Phytotherapy Phytopharmacology. 2022;104:154329.CrossRef Ji L, Su S, Xin M, Zhang Z, Nan X, Li Z, et al. Luteolin ameliorates hypoxia-induced pulmonary hypertension via regulating HIF-2α-Arg-NO axis and PI3K-AKT-eNOS-NO signaling pathway. Phytomedicine: Int J Phytotherapy Phytopharmacology. 2022;104:154329.CrossRef
13.
go back to reference Lázár Z, Mészáros M, Bikov A. The nitric oxide pathway in pulmonary arterial hypertension: pathomechanism, biomarkers and drug targets. Curr Med Chem. 2020;27(42):7168–88.CrossRefPubMed Lázár Z, Mészáros M, Bikov A. The nitric oxide pathway in pulmonary arterial hypertension: pathomechanism, biomarkers and drug targets. Curr Med Chem. 2020;27(42):7168–88.CrossRefPubMed
14.
go back to reference Porto Ribeiro T, Barbeau S, Baudrimont I, Vacher P, Freund-Michel V, Cardouat G et al. Piezo1 Channel Activation Reverses Pulmonary Artery Vasoconstriction in an Early Rat Model of Pulmonary Hypertension: The Role of Ca(2+) Influx and Akt-eNOS Pathway. Cells. 2022;11(15). Porto Ribeiro T, Barbeau S, Baudrimont I, Vacher P, Freund-Michel V, Cardouat G et al. Piezo1 Channel Activation Reverses Pulmonary Artery Vasoconstriction in an Early Rat Model of Pulmonary Hypertension: The Role of Ca(2+) Influx and Akt-eNOS Pathway. Cells. 2022;11(15).
15.
go back to reference Sood BG, Wykes S, Landa M, De Jesus L, Rabah R. Expression of eNOS in the lungs of neonates with pulmonary hypertension. Exp Mol Pathol. 2011;90(1):9–12.CrossRefPubMed Sood BG, Wykes S, Landa M, De Jesus L, Rabah R. Expression of eNOS in the lungs of neonates with pulmonary hypertension. Exp Mol Pathol. 2011;90(1):9–12.CrossRefPubMed
16.
go back to reference Malinovschi A, Ludviksdottir D, Tufvesson E, Rolla G, Bjermer L, Alving K, et al. Application of nitric oxide measurements in clinical conditions beyond asthma. Eur Clin Respiratory J. 2015;2:28517.CrossRef Malinovschi A, Ludviksdottir D, Tufvesson E, Rolla G, Bjermer L, Alving K, et al. Application of nitric oxide measurements in clinical conditions beyond asthma. Eur Clin Respiratory J. 2015;2:28517.CrossRef
17.
go back to reference Stocks J, Quanjer PH. Reference values for residual volume, functional residual capacity and total lung capacity. ATS Workshop on Lung volume measurements. Official Statement of the European respiratory society. Eur Respir J. 1995;8(3):492–506.CrossRefPubMed Stocks J, Quanjer PH. Reference values for residual volume, functional residual capacity and total lung capacity. ATS Workshop on Lung volume measurements. Official Statement of the European respiratory society. Eur Respir J. 1995;8(3):492–506.CrossRefPubMed
18.
go back to reference Oostveen E, MacLeod D, Lorino H, Farre R, Hantos Z, Desager K, et al. The forced oscillation technique in clinical practice: methodology, recommendations and future developments. Eur Respir J. 2003;22(6):1026–41.CrossRefPubMed Oostveen E, MacLeod D, Lorino H, Farre R, Hantos Z, Desager K, et al. The forced oscillation technique in clinical practice: methodology, recommendations and future developments. Eur Respir J. 2003;22(6):1026–41.CrossRefPubMed
19.
go back to reference Pilette C, Godding V, Kiss R, Delos M, Verbeken E, Decaestecker C, et al. Reduced epithelial expression of secretory component in small airways correlates with airflow obstruction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163(1):185–94.CrossRefPubMed Pilette C, Godding V, Kiss R, Delos M, Verbeken E, Decaestecker C, et al. Reduced epithelial expression of secretory component in small airways correlates with airflow obstruction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163(1):185–94.CrossRefPubMed
20.
go back to reference Ding Q, Mi BB, Wei X, Li J, Mi JY, Ren JT, et al. Small Airway Dysfunction in Chronic Bronchitis with preserved pulmonary function. Can Respir J. 2022;2022:4201786.CrossRefPubMedPubMedCentral Ding Q, Mi BB, Wei X, Li J, Mi JY, Ren JT, et al. Small Airway Dysfunction in Chronic Bronchitis with preserved pulmonary function. Can Respir J. 2022;2022:4201786.CrossRefPubMedPubMedCentral
21.
go back to reference Leonardi S, Parisi G, Papale M, Zicari AM, Olcese R, Licari A, et al. Small airways in children with allergic rhinoconjunctivitis: the potential role of a multicomponent nutraceutical. Acta bio-medica: Atenei Parmensis. 2020;91(2):350–5.PubMed Leonardi S, Parisi G, Papale M, Zicari AM, Olcese R, Licari A, et al. Small airways in children with allergic rhinoconjunctivitis: the potential role of a multicomponent nutraceutical. Acta bio-medica: Atenei Parmensis. 2020;91(2):350–5.PubMed
22.
go back to reference Spiekerkoetter E, Fabel H, Hoeper MM. Effects of inhaled salbutamol in primary pulmonary hypertension. Eur Respir J. 2002;20(3):524–8.CrossRefPubMed Spiekerkoetter E, Fabel H, Hoeper MM. Effects of inhaled salbutamol in primary pulmonary hypertension. Eur Respir J. 2002;20(3):524–8.CrossRefPubMed
23.
go back to reference Girgis RE, Champion HC, Diette GB, Johns RA, Permutt S, Sylvester JT. Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy. Am J Respir Crit Care Med. 2005;172(3):352–7.CrossRefPubMed Girgis RE, Champion HC, Diette GB, Johns RA, Permutt S, Sylvester JT. Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy. Am J Respir Crit Care Med. 2005;172(3):352–7.CrossRefPubMed
24.
go back to reference Malinovschi A, Henrohn D, Eriksson A, Lundberg JO, Alving K, Wikström G. Increased plasma and salivary nitrite and decreased bronchial contribution to exhaled NO in pulmonary arterial hypertension. Eur J Clin Invest. 2011;41(8):889–97.CrossRefPubMed Malinovschi A, Henrohn D, Eriksson A, Lundberg JO, Alving K, Wikström G. Increased plasma and salivary nitrite and decreased bronchial contribution to exhaled NO in pulmonary arterial hypertension. Eur J Clin Invest. 2011;41(8):889–97.CrossRefPubMed
25.
go back to reference Riley MS, Pórszász J, Miranda J, Engelen MP, Brundage B, Wasserman K. Exhaled nitric oxide during exercise in primary pulmonary hypertension and pulmonary fibrosis. Chest. 1997;111(1):44–50.CrossRefPubMed Riley MS, Pórszász J, Miranda J, Engelen MP, Brundage B, Wasserman K. Exhaled nitric oxide during exercise in primary pulmonary hypertension and pulmonary fibrosis. Chest. 1997;111(1):44–50.CrossRefPubMed
26.
go back to reference Olivieri M, Talamini G, Corradi M, Perbellini L, Mutti A, Tantucci C, et al. Reference values for exhaled nitric oxide (reveno) study. Respir Res. 2006;7(1):94.CrossRefPubMedPubMedCentral Olivieri M, Talamini G, Corradi M, Perbellini L, Mutti A, Tantucci C, et al. Reference values for exhaled nitric oxide (reveno) study. Respir Res. 2006;7(1):94.CrossRefPubMedPubMedCentral
27.
go back to reference Malekmohammad M, Folkerts G, Kashani BS, Naghan PA, Dastenae ZH, Khoundabi B, et al. Exhaled nitric oxide is not a biomarker for idiopathic pulmonary arterial hypertension or for treatment efficacy. BMC Pulm Med. 2019;19(1):188.CrossRefPubMedPubMedCentral Malekmohammad M, Folkerts G, Kashani BS, Naghan PA, Dastenae ZH, Khoundabi B, et al. Exhaled nitric oxide is not a biomarker for idiopathic pulmonary arterial hypertension or for treatment efficacy. BMC Pulm Med. 2019;19(1):188.CrossRefPubMedPubMedCentral
28.
go back to reference Bednarek M, Grabicki M, Piorunek T, Batura-Gabryel H. Current place of impulse oscillometry in the assessment of pulmonary diseases. Respir Med. 2020;170:105952.CrossRefPubMed Bednarek M, Grabicki M, Piorunek T, Batura-Gabryel H. Current place of impulse oscillometry in the assessment of pulmonary diseases. Respir Med. 2020;170:105952.CrossRefPubMed
29.
go back to reference Porojan-Suppini N, Fira-Mladinescu O, Marc M, Tudorache E, Oancea C. Lung function Assessment by Impulse Oscillometry in adults. Ther Clin Risk Manag. 2020;16:1139–50.CrossRefPubMedPubMedCentral Porojan-Suppini N, Fira-Mladinescu O, Marc M, Tudorache E, Oancea C. Lung function Assessment by Impulse Oscillometry in adults. Ther Clin Risk Manag. 2020;16:1139–50.CrossRefPubMedPubMedCentral
30.
go back to reference Rolla G, Brussino L, Bertero MT, Colagrande P, Converso M, Bucca C, et al. Increased nitric oxide in exhaled air of patients with systemic lupus erythematosus. J Rhuematol. 1997;24(6):1066–71. Rolla G, Brussino L, Bertero MT, Colagrande P, Converso M, Bucca C, et al. Increased nitric oxide in exhaled air of patients with systemic lupus erythematosus. J Rhuematol. 1997;24(6):1066–71.
31.
go back to reference Deerojanawong J, Leartphichalak P, Chanakul A, Sritippayawan S, Samransamruajkit R. Exhaled nitric oxide, pulmonary function, and disease activity in children with systemic lupus erythematosus. Pediatr Pulmonol. 2017;52(10):1335–9.CrossRefPubMed Deerojanawong J, Leartphichalak P, Chanakul A, Sritippayawan S, Samransamruajkit R. Exhaled nitric oxide, pulmonary function, and disease activity in children with systemic lupus erythematosus. Pediatr Pulmonol. 2017;52(10):1335–9.CrossRefPubMed
32.
go back to reference Fisher MR, Mathai SC, Champion HC, Girgis RE, Housten-Harris T, Hummers L, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum. 2006;54(9):3043–50.CrossRefPubMed Fisher MR, Mathai SC, Champion HC, Girgis RE, Housten-Harris T, Hummers L, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum. 2006;54(9):3043–50.CrossRefPubMed
33.
go back to reference Kielstein JT, Bode-Böger SM, Hesse G, Martens-Lobenhoffer J, Takacs A, Fliser D, et al. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol. 2005;25(7):1414–8.CrossRefPubMed Kielstein JT, Bode-Böger SM, Hesse G, Martens-Lobenhoffer J, Takacs A, Fliser D, et al. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol. 2005;25(7):1414–8.CrossRefPubMed
34.
go back to reference Dooley A, Gao B, Bradley N, Abraham DJ, Black CM, Jacobs M, et al. Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine. Rheumatology (Oxford). 2006;45(6):676–84.CrossRefPubMed Dooley A, Gao B, Bradley N, Abraham DJ, Black CM, Jacobs M, et al. Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine. Rheumatology (Oxford). 2006;45(6):676–84.CrossRefPubMed
35.
go back to reference Chen K, Popel AS. Vascular and perivascular nitric oxide release and transport: biochemical pathways of neuronal nitric oxide synthase (NOS1) and endothelial nitric oxide synthase (NOS3). Free Radic Biol Med. 2007;42(6):811–22.CrossRefPubMed Chen K, Popel AS. Vascular and perivascular nitric oxide release and transport: biochemical pathways of neuronal nitric oxide synthase (NOS1) and endothelial nitric oxide synthase (NOS3). Free Radic Biol Med. 2007;42(6):811–22.CrossRefPubMed
36.
go back to reference Cotton SA, Herrick AL, Jayson MI, Freemont AJ. Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin. J Pathol. 1999;189(2):273–8.CrossRefPubMed Cotton SA, Herrick AL, Jayson MI, Freemont AJ. Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin. J Pathol. 1999;189(2):273–8.CrossRefPubMed
37.
go back to reference Ibba-Manneschi L, Niissalo S, Milia AF, Allanore Y, Del Rosso A, Pacini A, et al. Variations of neuronal nitric oxide synthase in systemic sclerosis skin. Arthritis Rheum. 2006;54(1):202–13.CrossRefPubMed Ibba-Manneschi L, Niissalo S, Milia AF, Allanore Y, Del Rosso A, Pacini A, et al. Variations of neuronal nitric oxide synthase in systemic sclerosis skin. Arthritis Rheum. 2006;54(1):202–13.CrossRefPubMed
38.
go back to reference Santacruz JC, Mantilla MJ, Rodriguez-Salas G, Rueda I, Pulido S, Varela DC, et al. Interstitial lung disease in mixed connective tissue disease: an Advanced search. Cureus. 2023;15(3):e36204.PubMedPubMedCentral Santacruz JC, Mantilla MJ, Rodriguez-Salas G, Rueda I, Pulido S, Varela DC, et al. Interstitial lung disease in mixed connective tissue disease: an Advanced search. Cureus. 2023;15(3):e36204.PubMedPubMedCentral
Metadata
Title
Fractional exhaled nitric oxide in idiopathic pulmonary arterial hypertension and mixed connective tissue disease complicating pulmonary hypertension
Authors
Jianhua Xu
Xingxing Sun
Yuan Cao
Hanqing Zhu
Wenlan Yang
Jinming Liu
Jian Guo
Publication date
01-12-2024

Other articles of this Issue 1/2024

BMC Pulmonary Medicine 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.